ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its plan to conduct an Institutional Review Board (IRB) study that could fundamentally transform the cannabinoid edible and nutraceutical markets. The study is designed to demonstrate the dramatically enhanced efficacy of CBD-loaded exosomes in oral delivery. ...

Core Insights - NurExone Biologic Inc. is enhancing its engagement with the European financial and healthcare sectors by participating in three significant events, following the announcement of a potential third therapeutic indication for its lead drug asset, ExoPTEN [1][5] Group 1: Upcoming Events and Participation - CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a key investment conference for German-speaking markets, where the company will present its corporate strategy and pipeline development [2][3] - NurExone is also participating in the Healthtech Roadshow in Zurich from May 5-8, 2025, aimed at engaging healthcare professionals and life science investors in Switzerland [3] - From May 12-15, 2025, Dr. Shaltiel will present at BioProcess International Europe in Hamburg, discussing the company's exosome-based siRNA therapy and its ExoTherapy platform [4] Group 2: Strategic Goals and Growth Narrative - The participation in these events is designed to increase visibility for NurExone's innovative approach to regenerative medicine, particularly with the identification of a third potential indication for ExoPTEN, which enhances the company's growth narrative [5] - NurExone plans to maintain an active presence at key European conferences throughout 2025 to strengthen investor relations and foster strategic collaborations in the healthcare and biotech sectors [6] Group 3: Company Overview and Product Focus - NurExone Biologic Inc. is focused on developing exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing promising preclinical data for treating spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [7] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe, and has established Exo-Top Inc. as a U.S. subsidiary to support its North American growth strategy [7]